Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.

European journal of hospital pharmacy : science and practice - 23 Dec 2025

Mensah Samuel Akaakole, Ahmad Syed, Alruwaili Waleed, Raval Rutu, Gonuguntla Karthik, Patel Brijesh

Abstract excerpt

OBJECTIVES: There have been cases of cardiotoxicity induced by osimertinib in patients with non-small-cell lung cancer (NSCLC). However, limited data exist for a comprehensive cardiotoxicity profile analysis for osimertinib use in NSCLC patients. The aim of this study was to report the entire profile of cardiotoxicities after the initiation of osimertinib in consecutive patients with epidermal growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cardiotoxicity

Share to Cardiovascular Diseases

Share to ErbB Receptors

Share to Indoles

Share to Pyrimidines

Source

Identifiers

PMID: 39461730
DOI: 10.1136/ejhpharm-2024-004319

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.PMID 39461730Read ↗

Possible heart failure caused by osimertinib in a lung cancer patient.Semantic proximity Read ↗

Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.Semantic proximity Read ↗

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.Semantic proximity Read ↗

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case ReportSemantic proximity Read ↗

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Semantic proximity Read ↗

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read ↗

Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.Semantic proximity Read ↗

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.Semantic proximity Read ↗

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor OsimertinibSemantic proximity Read ↗

Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.